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economic consequences as hemodialysis patients. METHODS: A
total of 3067 adult predialysis patients with and without SHPT
were evaluated from January 1999 to December 2004 in a ret-
rospective matched cohort study using a patient-centric claims
database. Patients had a minimum 12-month pre-index and 6-
month follow-up after initial diagnosis of CKD and were
grouped into cohorts; cohort 1: without SHPT, cohort 2: with
SHPT. Annualized estimates of mean direct medical costs and
health care utilization, and time to dialysis or death following
index CKD diagnosis were compared. Generalized linear models
(GLM) with gamma distribution and a log link function were
used to assess differences in costs and GLM models with a neg-
ative binomial distribution were used to evaluate differences in
health care utilization. Kaplan-Meier survival analysis and Cox
proportional hazard models were used for time to dialysis and
death analysis. All multivariate models were adjusted for con-
founders: gender, age, plan type, payer type, geographic region,
physician specialty, pre-index co-morbidities, and pre-index total
health care costs. RESULTS: Generalized linear models revealed
CKD with SHPT had 3.61 times higher total costs, and 2.68
times more hospitalizations (p < 0.0001). Kaplan-Meier analysis
revealed that CKD with SHPT progresses more quickly to death
or dialysis. Cox models demonstrated that CKD with SHPT had
a signiﬁcantly higher risk of dialysis or death (HR = 5.05; 95%
CI = 4.08–6.24; p < 0.0001). CONCLUSION: SHPT in predial-
ysis patients without VDR activator therapy is associated with
signiﬁcantly greater direct total costs, inpatient hospitalizations,
and disease progression compared to patients without SHPT and
VDR activator therapy.
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OBJECTIVES: Chronic kidney disease (CKD) can adversely
affect workforce productivity and increase the economic burden
on employers. This analysis quantiﬁes the incremental direct
(medical, pharmacy) and indirect (sick leave, disability) health
care costs of pre-dialysis CKD patients from an employer’s per-
spective. METHODS: A retrospective analysis was conducted
using eligibility, medical, pharmacy and disability claims data
from 31 large US employers for approximately 5 million beneﬁ-
ciaries between January 1998 and January 2005. A total of
10,219 pre-dialysis CKD patients (deﬁned as ≥2 claims contain-
ing an ICD-9 diagnosis code for CKD less than 90 days apart,
with no history of organ transplant) were identiﬁed. These
patients were observed from the time (month) of their CKD diag-
nosis to the month preceding their ﬁrst renal dialysis claim, dis-
enrollment or study end date (whichever occurred ﬁrst). A
representative random sample of 171,207 individuals without
CKD was selected as controls. Employer costs were based on
direct medical and pharmacy costs as well as the indirect costs,
which measure employee productivity loss. Tobit regressions,
which correct for non-normality of costs, including controls for
age, gender, health plan, location, liver cirrhosis, hypertension,
chemotherapy, and Charlson Comorbidity Index, were con-
ducted. RESULTS: The unadjusted ratios of mean direct and
indirect costs for pre-dialysis CKD patients compared to controls
were 8.4 : 1 ($1671 vs. $200 per patient-month, p < 0.0001) and
5.8 : 1 ($406 vs. $70 per patient-month, p < 0.0001), respectively.
After controlling for confounding factors, the adjusted ratios
remained signiﬁcant at 4.3 : 1 ($651 incremental monthly cost, p
< 0.0001) for direct costs, and 3.3 : 1 ($157 incremental monthly
cost, p < 0.0001) for indirect costs. CONCLUSION: Both the
unadjusted and adjusted ratios for mean direct and indirect costs
for pre-dialysis CKD patients compared to non-CKD patients
indicated that pre-dialysis CKD resulted in statistically signiﬁ-
cant increases in both direct and indirect costs to the employer.
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OBJECTIVES: Anemia is a treatable and often preventable com-
plication of CKD, but is often under-diagnosed and under-
treated. This analysis evaluated the direct medical and indirect
work productivity (disability and sick leave) costs before and
after the diagnosis of anemia in pre-dialysis CKD patients.
METHODS: Anonymous health and disability claims from 31
U.S. employers between January 1998 and January 2006 from
∼5 million individuals were used to identify 3449 pre-dialysis
CKD patients <65 years of age with ≥2 anemia diagnosis claims.
The study period was deﬁned as the time from the ﬁrst CKD
claim until the earliest of disenrollment, initiation of dialysis,
organ transplantation, or study end. Average per member per
month (PMPM) costs were computed before and after the month
when anemia was ﬁrst diagnosed. All costs were calculated 
from employers’ perspectives. RESULTS: Average direct and
indirect PMPM costs were respectively $3293 and $501 three
months prior to the ﬁrst anemia diagnosis, $7445 and $838 
at the time of diagnosis, and $1794 and $365 twelve months
after diagnosis. Increases in inpatient costs were the largest driver
for the cost changes over time. Direct and indirect PMPM 
costs increased more than two-fold in the three months prior 
to the ﬁrst anemia diagnosis, leading to a cost peak at the time
of diagnosis, and gradually decreased over time to reach cost
levels similar to those observed twelve months before diagnosis.
CONCLUSION: Direct and indirect costs occurring as early 
as three months before the formal diagnosis of anemia in pre-
dialysis CKD patients could be associated with prodromes 
of anemia or late diagnosis. These costs peaked at time of diag-
nosis. Declining costs after diagnosis could suggest beneﬁts of
diagnosis and/or treatment of anemia. Further studies are needed
to evaluate whether earlier diagnosis and treatment of anemia
could reduce or prevent cost escalations in pre-dialysis CKD
patients.
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OBJECTIVES: Systemic lupus erythematosus (SLE) is an autoim-
mune disorder that can affect any system of the body. Kidney
Involvement, lupus nephritis (LN), affects up to 50% of SLE
patients during the course of their disease, and is characterised
by periods of active disease (ﬂares) and remission. For patients
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with more severe nephritis, an induction course of immuno-
suppressive therapy is recommended—typically, intravenous
cyclophosphamide (IVC) or mycophenolate mofetil (MMF), fol-
lowed by a maintenance course, typically of azathioprine. The
objective is to determine which induction therapy results in
better quality of life for patients, and which represents best value
for money. METHODS: A patient-level simulation is used to
model the total costs and QALYs gained of a patient treated with
either IVC or MMF for an induction period of six months. Efﬁ-
cacy data are extracted from a systematic review of randomised
controlled trials, and utility, resource and unit cost data from
published sources and standard databases. The perspective and
setting of the model is the English NHS and the price year, 2005.
An incremental analysis demonstrates the relative cost-effective-
ness of the two options. RESULTS: On average, MMF is more
effective (resulting in improved quality of life) when compared
with IVC (mean 0.039 QALYs gained over six months). MMF
therapy is less expensive overall than IVC, on average ≤1600 less
over the period. Therefore, MMF dominates IVC. The major
determinant and cost driver of this result is the requirement for
a day-case procedure to administer IVC. Analysis of uncertainty
shows an 81% probability that MMF will be cost-effective 
compared with IVC at a willingness to pay of approximately
.21230,000 per QALY gained. CONCLUSION: Treatment with
MMF is likely to be more effective and less expensive overall
than IVC as induction therapy for LN.
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OBJECTIVES: Hemodialysis (HD) and peritoneal dialysis (PD)
are the two main types of dialysis therapy performed on patients
with ESRD. The United States Renal Data System (USRDS) pro-
duces, among a host of other types of data, annual State-level
data related to dialysis and hospitalizations. Panel data sets
(cross-sectional time series) can be created from these USRDS
data to estimate the impact of dialysis therapy on hospitalization
rates at an aggregate level. The objective of this study is to assess
the relationship of hospitalizations and dialysis therapies using
USRDS State-level data. METHODS: Data used in the analysis
were obtained from the 1999 through 2005 Annual Data
Reports on the USRDS Web site. The data covers the ﬁfty states
plus Washington D.C. for the years 1997 through 2003. Regres-
sion analysis was performed on the panel data using the
TSCSREG procedure in SAS 9.1. A one-way ﬁxed effects model
was used. The dependent variable was the Standardized Hospi-
talization Ratio (SHR). SHR is the ratio of observed over
expected hospitalization events in the ESRD population. The
independent variables included in the regression analysis were
dialysis modality, demographics, and other State-level data.
RESULTS: The adjusted R2 for the estimated regression model
was 0.88. The results showed that the percent of dialysis patients
on PD was negatively associated with SHR (p < 0.01) whereas
HD was positively associated with SHR (p < 0.01). In addition,
an interaction term between the percent of the ESRD population
with diabetes and the percent of the State population under 65
years of age was positively associated with SHR (p < 0.0001).
CONCLUSION: A robust econometrics model on aggregate
State-level USRDS data showed PD was negatively associated
with hospitalization. Policymakers and payers need to carefully
consider the impact of health care policy on dialysis modality
choice and thus on costs.
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OBJECTIVES: Women with chronic kidney disease (CKD) are
often at risk of having anemia. This study examined the varia-
tion in anemia care of CKD among women in outpatient settings
in the U.S. METHODS: This cross-sectional study used data
from the National Ambulatory Medical Care Survey (NAMCS)
from 1996–2003. Women aged 18 years and older with CKD
were included in the study sample based on clinical diagnoses
and the reason for the visit. Anemia diagnoses were retrieved
using clinical diagnoses and anemia-related medications 
(Erythropoietic stimulating agents or iron replacement) were
retrieved using the NAMCS drug codes. All analyses were
weighted to make national estimates. RESULTS: There were
approximately 58 million weighted outpatient visits for women
with CKD in the outpatient settings from 1996 to 2003. Nearly
14% of these visits were related to Hispanics and 50% of these
visits were by patient aged 65 years and older. Nephrologists
accounted for only 15% of CKD patient visits and 58% of these
patients had a diagnosis of anemia. Only 11% of visits with
anemia resulted in prescription for anemia related medication
(erythropoietin stimulating agents or iron replacement). Women
with Medicare coverage were 2.6 times more likely (p ≤ 0.05) to
be seen by nephrologists. Women seen by nephrologists were 2.4
times more likely (p ≤ 0.05) to receive a prescription for an ery-
thropoietin stimulating agent compared to patients seen by non-
nephrologists. Additionally, PCPs were less likely (p ≤ 0.05) to
prescribe erythropoietin stimulating agents compared to non-
PCPs. CONCLUSION: The ﬁndings of this study suggest that
PCPs are less likely to prescribe anemia medications in US out-
patient settings compare to non-PCPs. Increased awareness of
the impact of early treatments of anemia among women with
CKD is needed in outpatient settings in the U.S.
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OBJECTIVES: To understand current real-world utilization of
erythropoietic agents, this study examined epoetin alfa (EPO)
and darbepoetin alfa (DARB) dosing patterns and treatment
costs in elderly patients with chronic kidney disease (CKD) not
receiving dialysis. METHODS: A retrospective analysis was con-
ducted using medical claims from approximately 35 health plans
nationwide during the period of January 2004 through Febru-
ary 2006. To be included in the analysis, patients were required
to be ≥65 years old, have ≥2 EPO or DARB claims, have a CKD
diagnosis within 90 days prior to EPO or DARB initiation, and
be newly initiated on either agent. If a patient received renal dial-
ysis, data were censored 30 days prior to the ﬁrst date of dialy-
sis. Patients diagnosed with cancer or that received
chemotherapy were excluded. Mean weekly doses weighted by
treatment duration were used to calculate drug costs based 
